Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.55 |
| ▸ | PPARG | P37231 | 4/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24847857 | 0.88 | PPARA (0.51) | PPARAPPARGHDAC1HDAC6CNR1 | |
| SCHEMBL26224287 | 0.87 | PPARA (0.49) | PPARAPPARGHDAC1HDAC6CNR1 | |
| SCHEMBL23845447 | 0.87 | PPARA (0.49) | PPARAPPARGHDAC1HDAC6CNR1 | |
| SCHEMBL27018409 | 0.85 | PPARA (0.59) | PPARAPPARGHDAC1HDAC6CNR1 | |
| SCHEMBL26203877 | 0.84 | HDAC6 (0.51) | PPARAPPARGHDAC1HDAC6CNR1 | |
| SCHEMBL22525841 | 0.83 | PPARA (0.57) | PPARAPPARGHDAC1HDAC6CNR1 | |
| SCHEMBL26203900 | 0.83 | FOS (0.47) | PPARAPPARGHDAC1HDAC6CYP2D6 | |
| SCHEMBL25122747 | 0.82 | CNR2 (0.46) | PPARAPPARGCNR1CNR2 | |
| SCHEMBL25123387 | 0.81 | CNR2 (0.45) | CNR1CNR2 | |
| SCHEMBL25123317 | 0.81 | CNR2 (0.45) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | PPARA 3484/4885PPARG 3324/4885HDAC1 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.